ASCO 2013 - Poster: Hematologic safety of radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial

CHICAGO, IL USA ( - Presented by C. Parker,1 J. Garcia-Vargas,2 C.G. O’Bryan-Tear,3 F. Fang,2 N.J. Vogelzang4 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 Parker ra223 poster thumb

1The Royal Marsden NHS Foundation Trust, Sutton, UK; 2Bayer HealthCare, Montville, NJ, USA; 3Algeta ASA, Oslo, Norway; 4Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage